Ginj M[au] - Search Results

Year	Number of Results
2003	1
2004	1
2005	3
2006	3
2007	2
2008	1
2010	2
2012	1
2014	1
2016	1
2021	1
2022	1
2023	0

1

Evaluation of available in vitro 99mTc-RBC labeling techniques: a Canadian perspective.

Toda E, Ginj M. Toda E, et al. Among authors: ginj m. J Nucl Med Technol. 2014 Dec;42(4):243-4. doi: 10.2967/jnmt.114.148650. Epub 2014 Nov 13. J Nucl Med Technol. 2014. PMID: 25472511 Free article. No abstract available.

2

Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.

Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Borgna F, et al. Among authors: ginj m. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34625828 Free PMC article.

3

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.

Boubaker A, Prior JO, Willi JP, Champendal M, Kosinski M, Bischof Delaloye A, Maecke HR, Ginj M, Baechler S, Buchegger F. Boubaker A, et al. Among authors: ginj m. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1868-75. doi: 10.1007/s00259-012-2210-0. Epub 2012 Sep 1. Eur J Nucl Med Mol Imaging. 2012. PMID: 22940856

4

Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.

Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, Schulz S, Maecke HR. Ginj M, et al. Chem Biol. 2006 Oct;13(10):1081-90. doi: 10.1016/j.chembiol.2006.08.012. Chem Biol. 2006. PMID: 17052612

5

Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.

Antunes P, Ginj M, Walter MA, Chen J, Reubi JC, Maecke HR. Antunes P, et al. Among authors: ginj m. Bioconjug Chem. 2007 Jan-Feb;18(1):84-92. doi: 10.1021/bc0601673. Bioconjug Chem. 2007. PMID: 17226960

6

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Antunes P, et al. Among authors: ginj m. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93. doi: 10.1007/s00259-006-0317-x. Epub 2007 Jan 16. Eur J Nucl Med Mol Imaging. 2007. PMID: 17225119 Free article.

7

Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S. Pöll F, et al. Among authors: ginj m. Mol Endocrinol. 2010 Feb;24(2):436-46. doi: 10.1210/me.2009-0315. Epub 2010 Jan 5. Mol Endocrinol. 2010. PMID: 20051480 Free PMC article.

8

Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB, Yapp DT. Dragowska WH, et al. Among authors: ginj m. Sci Rep. 2016 Jan 4;6:18537. doi: 10.1038/srep18537. Sci Rep. 2016. PMID: 26727049 Free PMC article.

9

New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.

Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR. Ginj M, et al. Clin Cancer Res. 2008 Apr 1;14(7):2019-27. doi: 10.1158/1078-0432.CCR-07-1687. Clin Cancer Res. 2008. PMID: 18381940

10

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC. Cescato R, et al. Among authors: ginj m. J Nucl Med. 2006 Mar;47(3):502-11. J Nucl Med. 2006. PMID: 16513620 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results